Implantable Venous Access Port Market Report: Trends, Forecast and Competitive Analysis to 2035

Implantable Venous Access Port Market

The future of the global implantable venous access port market looks promising with opportunities in the intravenous chemotherapy and nutritional support treatment markets. The global implantable venous access port market is expected to reach an estimated $921.8 million by 2035 from $609.8 million in 2027 with a CAGR of 2.7% from 2027 to 2035. The major drivers for this market are the increasing prevalence of chronic diseases, the rising demand for long-term intravenous access, and the growing adoption of minimally invasive procedures.

• Lucintel forecasts that, within the type category, titanium infusion port is expected to witness higher growth over the forecast period due to better biocompatibility and durability of infusion ports made of titanium.
• Within the application category, intravenous chemotherapy is expected to witness higher growth over the forecast period due to increasing prevalence of cancers requiring repeated IV chemotherapy.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to increasing population of cancer patients and the expanding oncology service facilities.

Emerging Trends in Implantable Venous Access Port Market

Between 2025 and 2027, the IVAP market will evolve from a procedure-focused to a value-focused model. Most hospitals have initiated or expanded outpatient cancer treatment programs and have focused on the use of devices that minimize the risk of health care associated infections. Of all the oncology-related services offered by hospitals, the oncology service line is expected to maintain its dominant position during the forecast period. Lucintel anticipates that in addition to evidence and service, manufacturing also will play an important role in competition.

• Infection Prevention: There is a strong market trend towards the use of antimicrobial and/or needleless catheter systems. Even though health care associated infections are preventable, many hospitals still experience catheter-related blood stream infections (CRBSIs). Providers are shifting to the purchase of products that will aid in the prevention of CRBSIs. It is expected that infection prevention port selection will be the norm within the next three to five years.
• Outpatient Oncology: Due to advances in pharmacology, more and more oncology and hematology related therapies will be administered on an outpatient basis. The use of IVAPs will provide access over a long period of time and will allow the patient to be comfortable during treatment.
• Standardizing Devices: Manufacturers are standardizing elements of their medical devices based on feedback from hospitals. This feedback has focused on reducing the number of variations of a particular device and simplifying the training needed for a given device. One facet of medical device standardization has been advancing the port speed of devices. The focus of the standard has been on devices rated to operate at speeds of up to 5 mL/s. The standard will be reviewed by 2025, and in the interim, the focus of device procurement will be based on the compliance of the device with the standard rather than price.
• Resilient Supplies: Purchasing organizations will seek multiple suppliers for a given device. The purchasing organization's reliance on a single supplier for a device was demonstrated during the COVID-19 pandemic to increase supply chain risk. While supplier price and cost will increase during this period, the purchasing organizations will qualify a larger number of suppliers based on the availability of the device and the organizations' willingness to carry additional supply.
• Pricing and Premium Ports: The competition for premium ports has shifted focus from marketing to the design and development of ports and access devices for medical procedures that integrate clinical data. Long-term usability has become a differentiator for ports and access devices. In the short term, hospitals will be willing to pay a premium for devices that integrate usability features that improve workflow and reduce the number of interventions needed for a given procedure.

Due to the impact of cancer and the lengthy and complex treatment, the demand for medical devices is expected to increase. Devices will be purchased based on the cost and the overall impact on the medical facility. A greater focus on clinical outcomes is expected. Dependable, regional medical device suppliers are expected to increase market share.

Recent Developments in the Implantable Venous Access Port Market

Stable Growth is expected to occur in the IVAP market between the years 2025-2027 due to more cancer patients being diagnosed, longer treatment durations, and the preference by hospitals to use more permanent vascular accesses. Lucintel expects that the market will continue to grow, however, the main focus should be more on the value of the market as opposed to the volume. Safety, ease of placement, and product variety will continue to drive market competition.

• Capacity Expansion: A manufacturer based in Europe announced in February 2025 that they would be increasing their production capacity of sterile devices used for oncology access by 20%. This was expected to help meet the growing demand for their devices.
• Acquisition Activity: In May 2025, a different manufacturer announced the acquisition of a catheter-placement device company for 150 million dollars. It is expected that larger companies will acquire smaller companies in order to gain more business variety and strength.
• Technology Launch: In June 2025, a different manufacturer released a medical port that has a flow rate of 5 ml per second. It is expected that ports with this technology will help reduce the number of medical device workshops that are performed.
• Strategic Collaboration: A port manufacturer and a hospital network with 30+ locations partnered in September 2025 to track the performance of catheters. Hospital purchasing committees are increasingly evaluating products based on the total cost to administer the therapy (including the infection risk and the average dwelling time of the catheter).
• Government Approval: In January 2026, a regulatory agency granted a port system with 10-years' implantable claim. Longer duration port systems may lead to expanded use by patients requiring repeated infusion therapies.

It is expected that in the coming five years, the market will comprehend catheter systems that enable the integration of safe, effective and efficient vascular access with lower complication rates. The oncology market will continue to be the largest market for infusion catheters; however, other markets, especially outpatient infusion and long term/repetitive infusion therapies will also experience growth. Evidence based on real world data will be the determining factor in long term contracts.

Strategic Growth Opportunities in the Implantable Venous Access Port Market

Between 2024 and 2026, various trends in the cancer industry will create opportunities for the implantable venous access port market. These include increasing rates of cancer, hospitals and healthcare systems transitioning to outpatient infusion and/or primary cancer treatment, and healthcare systems evaluating the total cost of cancer treatment. Based upon information from Lucintel, the market will also benefit from the increasing demand for safety and quality, expansion of port indications, and the adoption of a service-based model. Clinical and economic integration will play a role in the differentiation of medical device port suppliers.

• Paediatric and Neonatal Applications: A safer, lower-profile medical port for frequent chemotherapy or nutritional infusion would help children and teens as well as younger cancer patients. According to the American Cancer Society, approximately 9,550 children will be diagnosed with cancer in 2025.
• Home Infusion Expansion: The market for medical ports would also benefit from the increasing trend of patients receiving infusion therapies in the home. In March 2025, the National Home Infusion Association reported that there were more than 3,000 provider agencies in the U.S. and territories.
• Premium Products: Antimicrobial-coated and other infection-reducing products, such as catheters, will be more expensive due to hospital reimbursement cuts associated with reductions in bloodstream infections and readmission rates. In April 2025, the CDC reported on central line associated bloodstream infections and encouraged the purchase of high-risk, high-return products for the prevention of such infections.
• Ambulatory Oncology Centres: The growing demand for cancer treatment and the shift of oncology care to the outpatient setting increases the need for faster and easier methods of vascular access. The U.S. is projected to have more than 2 million new cases of cancer in 2025.
• Training and Distribution in High-Growth Markets: Further development of more affordable access devices and their incorporation into outpatient care in more high-growth market countries, where access is currently restricted to tertiary care centres, is expected. In 2025, the World Bank reported that markets with a higher-middle income status represented more than 75% of the world's population.

During the next five years, there will be significant new opportunities for companies to enter the global market with safe and affordable access products for the delivery of cancer treatment and other care requiring the use of access port products.

Implantable Venous Access Port Market Drivers and Challenges

The market for implantable venous access ports is set to benefit from various factors including advancements in medical technology, increase in the number of people with chronic conditions, growing investments in healthcare, and alterations in regulatory frameworks. There is growing need for reliable, long-term, venous access in the field of oncology and auscultatory care.

The factors responsible for driving this market include:

• Patient Demand: Long term effects of cancers and other chronic conditions, prolonged treatment and more oncological and infusion therapies provided outside of a hospital, have increased the need for long term intravenous access. Implantable venous access ports aid in the insertion of IV lines for administration of chemotherapeutic and other infusion therapies as well as blood transfusions and sampling. According to the World Health Organization, in 2022, more than 20 million cases of cancer were reported and each year the global burden of cancer is expected to increase.
• Technology Improvement: Improvements in materials science has improved the design of port chambers, catheters and other components of infusion devices. Further, advances have been made in needle-resistant and radio-opaque infusion devices. As a result, device manufacturers are able to design devices that are not only safer but more easily used by clinical staff. Also, device manufacturers have developed port systems that are more anatomically appropriate for children and other fragile patients. Innovations in implantation systems and techniques have reduced the risk of complications. Many of these innovations are focused on improving the durability of implantable infusion devices. These innovations have increased the demand for infusion devices and have enabled the use of premium infusion devices.
• Revision of Regulations and Clinical Guidelines: A greater emphasis on regulations for the post-market surveillance of infusion devices, combined with the increased availability of clinical guidelines, have improved the confidence of the healthcare community in implantable infusion devices. This has reduced the number of needless complications. During this period, many healthcare facilities transitioned to using evidence-based devices and abandoned devices for which there was no evidence to support their use. The same trend was observed in other regulated industries.
• Outpatient Care Infrastructure: Outpatient cancer care, home-based infusion services, and other ambulatory services have expanded. Like inpatient services, outpatient infusion services have a growing need for long-term vascular access. A port allows outpatient infusion services and decreases length of stay on inpatient services. The U.S. has over 6000 certified ambulatory surgery centres. Ports allow patients to receive repeated infusion services and reduce overall costs. Decentralized services increase the need for products that are designed to be maintained by the consumer. The next three to five years will increase the need for portable vascular access devices.
• Supply and Demand: Increased competition and improvement in the manufacturing and supply of medical devices leads to a greater variety of products. Some of these improvements include the incorporation of antimicrobial covers, and other design features that allow power injection and portability. In June 2025, there was a continued trend of health care institutions and suppliers implementing a strategy of dual supplier for Medical Devices. Improvement in manufacturing will allow better pricing and increased availability of these medical devices.

The challenges facing this market include:

• Catheter-related Infections and Related Complications: Bloodstream infections remain a concern. Other complications include clots and blockages. While new methods to insert and maintain central catheter lines have lowered complication rates, complications may still occur and require hospitalization and/or port removal. The Centers for Disease Control and Prevention recommends the use of standard techniques for central line insertions, and access-site assessments. Antimicrobial ports and other devices that incorporate additional features to prevent infection, along with staff training, will likely be purchased in the next three to five years.
• Costs Associated with Procedures and The Total Cost of Care: Central catheter lines require several procedures and increase the cost of care. In lower-income countries, the high cost may limit the use of central catheter lines. Even in higher-income countries, costs may not be fully covered. In the next three to five years, ports that reduce the overall cost of care by reducing the total number of procedures needed and complications that require treatment to be postponed or interrupted will likely be utilized.
• Supply Chain and Regulatory Complexity: Supply disruptions and the longest delays in the medical device supply chain are attributed to specialized polymers and metals, surface coatings, and final product sterilization. Other complexities include global regulatory variations and strict quality requirements. In September 2025, many device manufacturers continued to stockpile device inventories, largely due to persisting international supply chain disruptions and variability in Logistics. It is anticipated that during the next 3 to 5 years, device manufacturers with regionally diverse supplier networks, and production and digital traceability, and advanced regulatory and Health Authority approvals and engagements, will be best positioned to keep device inventories continuously available.

Improving technology, health care infrastructure investments and other factors will allow health care providers to deliver safe and more effective access to care outside of traditional health care facilities. While many barriers will be overcome to provide safer and better access to care, other barriers, including infection risk, cost, reimbursement, and supply and regulation, will continue to constrain the access port device market. Factors that will differentiate access device market competitors will be production and distribution.

List of Implantable Venous Access Port Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies implantable venous access port market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the implantable venous access port market companies profiled in this report include-

• BD
• AngioDynamics
• ICU Medical
• B. Braun Medical
• PFM Medical
• Vygon
• Districlass
• PakuMed
• Linhua Medical
• Fresenius

Implantable Venous Access Port Market by Segment

The study includes a forecast for the global implantable venous access port market by type, application, and region.

Implantable Venous Access Port Market by Type [Value ($M) from 2019 to 2035]:

• Titanium Infusion Port
• Plastic Infusion Port

Implantable Venous Access Port Market by Application [Value ($M) from 2019 to 2035]:

• Intravenous Chemotherapy
• Nutritional Support Treatment

Implantable Venous Access Port Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Implantable Venous Access Port Market

The implantable venous access port market is being affected by different trends including the need for Long Term venous access devices for cancer treatment. Other trends include tighter regulations by governments, and on-site manufacturing of medical devices. There are ongoing efforts to improve the safety and reliability of power injection devices, and address challenges in the device supply chain. Lucintel expects these efforts will help companies enhance their competitive positions in the market.

• United States: Recently, the focus has been on improving medical ports to allow power injection of 5mL. Examples include products in the BD PowerPort product line. These port developments are essential, especially with the rising trend of performing oncology treatments at outpatient and cancer infusion centres.
• China: Similar to the United States, the focus in China has been on strengthening local manufacturing of infusion ports and catheters. In 2025, MicroPort reported having over 20,000 employees, and in the next 3-5 years it is expected that they and other Chinese device companies will improve the local supply of infusion ports to compete with imported infusion ports.
• Germany: Though Celsite ports systems remain aligned to EU MDR requirements, process to update other product lines is ongoing. From May 2024, most legacy devices would require compliance with MDR. This highlights importance of traceable manufacturing and certification for implantable devices.
• India: The FY2025 disclosures of Poly Medicure Ltd. indicate capital expenditures for expansion of manufacturing capabilities and further investments in its product portfolio, which already includes implantable access products (March 2025). Increasing local manufacture of vascular access products is expected to improve the safety and quality of India's health-care services.
• Japan: With consolidated net sales of approximately 1 trillion yen in fiscal 2025 (March 2026), Terumo Corporation continued to strengthen its interventional and other hospital products while keeping its vascular access devices manufacturing and supplying business. Reliable and safe vascular access products are of high importance for the Japanese population, which is significantly aging and in which cancer prevalence is high.

Features of the Global Implantable Venous Access Port Market

• Market Size Estimates: implantable venous access port market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: implantable venous access port market size by type, application, and region in terms of value ($B).
• Regional Analysis: implantable venous access port market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the implantable venous access port market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the implantable venous access port market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the implantable venous access port market by type (titanium infusion port and plastic infusion port), application (intravenous chemotherapy and nutritional support treatment), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?